Kornimate/medical-research-clean huggingface dataset:
early detection of anthracycline cardiotoxicity by echocardiographic analysis of myocardial deformation in 2d strain

Conditions: Leukemia; Cardiac Toxicity

Summary: it is now accepted that the anticancer properties of anthracyclines were allowed in many malignancies improve the prognosis of affected populations. however, the cardiotoxicity of anthracyclines is responsible for an interruption of this treatment by alteration of potentially irreversible myocardial contraction and high mortality. an earlier detection of adverse myocardial anthracycline chemotherapy would allow the adaptation of the regimen by reducing the number of interruptions of antitumor and strengthening monitoring. optimizing the therapeutic antitumor and generate an increase in survival of patients treated.

analysis of myocardial deformation in its longitudinal component, circumferential and radial, is a new echocardiographic technique for evaluating myocardial function, which has demonstrated its superiority compared to lvef in many clinical situations. it therefore seems promising to evaluate this new tool in the earlier detection of adverse myocardial chemotherapy with anthracyclines. the ultimate goal is indeed to determine a reliable and reproducible parameter for cardiac toxicity diagnostic to avoid chemotherapy interruption, thus improving the survival of these patients. the main objective of this project is to evaluate the association between changes in myocardial deformation longitudinal 2d strain echocardiography between baseline and 6 weeks after initiation of anthracycline therapy for acute leukemia and the occurrence of impaired left ventricular function within 12 months after starting treatment. it is a prognostic study of clinical-looking, without randomization. the inclusion will take place over a period of 12 months with a total follow-up of 12 months. the analysis will focus on the identification of parameters predictive of alteration of fe vg.

Eligibility criteria:
inclusion criteria: * patient female or male aged between 18 and 65 * patients with a haematological disease and ran for a first-line chemotherapy including anthracycline * patients with a predict cardiovascular score to 10 years below 20% or if higher, with a stress echocardiography using dobutamine, negative, for less than six months. * patient or affiliate receiving social security * patient informed consent and having oral and written exclusion criteria: * a history of chemotherapy or radiotherapy of the left hemithorax * significant coronary artery disease: a history of angioplasty, stent, cabg, predict cardiovascular score to 10 years over 20% of stress echocardiography and dobutamine positive (three positive segments) * left ventricular hypertrophy (diastolic septum ≥ 10 mm and diastolic posterior wall ≥ 10 mm) * one or more significant valvulopathy: rao, rm medium or tight, im, it and cai ≥ grade 2 * secondary or primary cardiomyopathy (lvef ≤ 50%) * pregnant or lactating
prevalence and epidemiology of nosocomial candidaemia and antifungal susceptibility patterns in an italian tertiary-care hospital

Conditions: Candidemia

Summary: during the past two decades, the frequency of invasive fungal infections has increased dramatically in hospitalised patients throughout the world, and candida has now emerged as one of the leading causes of bloodstream infections (bsis). risk-factors for invasive candidiasis include improvements in intensive care strategies (i.e., central venous catheters, mechanical ventilation, hyper-alimentation), prolonged stays in intensive care units (icus), the development of more aggressive surgical techniques, and the prolongation of survival of critically-ill patients. two other important factors, observed mainly in cancer patients, are colonization of mucous membranes by yeasts, and neutropenia, resulting from increased use of antibiotics and anti-neoplastic agents, respectively. the crude mortality rate of candidaemia is high (38-75%), and the attributable mortality has been estimated at 25-38%. during the past 15 years, the prevalence of infections caused by non-albicans candida spp. has increased exponentially, so that these organisms now account for \> 50% of episodes of fungaemia in various surveys. the increase in invasive fungal infections, the associated high mortality rate, and the emergence of antifungal resistance, have all driven the search for more potent antifungal drugs. the aims of the present study are to investigate the prevalence and the epidemiology of candidaemia and to determine the antifungal susceptibility patterns of candida spp. isolates from a tertiary-care hospital in italy.


Eligibility criteria:
inclusion criteria: * patients diagnosed with a nosocomial candidaemia at the university hospital of modena, italy, between january 1998 and march 2008

Keywords: fungal susceptibility
a prospective, pilot evaluation of device equivalence

Conditions: Wound

Summary: patients with chronic wounds will be imaged using 3 imaging devices. two types of images will be acquired with each device, as standard photograph (st-image) and a fluorescence image (fl-image). the images captured with the 3 imaging devices will be compared off-line by 5 interpreters to assess for any differences in the images that would alter a clinical decision.

patients (n = 50) with chronic wounds will be imaged using 3 imaging devices. two types of images will be acquired with each device, as standard photograph (st-image) and a fluorescence image (fl-image). the images captured with the 3 imaging devices will be compared off-line by 5 interpreters to assess for any differences in the images that would alter a clinical decision.

Eligibility criteria:
inclusion criteria: * subjects (inpatient/outpatient) presenting with a wound * wound size less than 15 cm in length * 18 years or older exclusion criteria: * treatment with an investigational drug within 1 month before study enrolment * subjects with recent (\<30 days) biopsy or curettage of target wound * subjects with wounds that cannot be completely imaged by study device due to anatomic location * unable or unwilling to consent
online programs to promote colon cancer screening

Conditions: Colon Cancer Screening

Summary: to evaluate online peer support and colorectal cancer screening behavior among individuals who are not currently meeting colorectal cancer screening guidelines. this is a randomized controlled trial.

participants in the control group will view standard online information about colon cancer screening. participants in the intervention group will view the same information and also will be invited to sign on to the online website and interact with peer supporters at their convenience. they will have 6 months to communicate with peer supporters. peer supporters are encouraged to address comments and concerns of the study participants. about 300 study participants, majority white, female. inclusion criteria: age 50-75, not currently meeting colorectal cancer screening guidelines, no previous colorectal cancer. the study will also include 15 previously identified peer supporters. recruitment: administrators of the sparkpeople.com weight loss community will send study recruitment emails to members at least 50 years of age. interested individuals will pass an eligibility screening and provide informed consent.

Eligibility criteria:
inclusion criteria: 1. age 50-75 2. not currently meeting colorectal cancer screening guidelines 3. no previous colorectal cancer.

Keywords: colon cancer screening
validation of the catquest-9sf questionnaire in greek language

Conditions: Cataract; Catquest-9SF

Summary: primary objective of this study is the validation of the catquest-9sf questionnaire in the greek population.

the present study aims to validate the catquest-9sf questionnaire in the greek population. the catquest-9sf is a questionnaire for assessing the quality of vision of patients with cataract. it consists of 9 questions, two of which concern the subjective assessment of the patient's vision and the other seven the patient's ability to perform various daily activities. the catquest-9sf questionnaire were translated into the greek language by a translation team consisting of five members: one translation coordinator, two professional native english-speaking translators, one professional native greek-speaking translator and one native greek ophthalmologist fluent in english. patients participating in the study are asked to complete a questionnaire in greek before and after cataract surgery. upon completion of the data collection, data are processed and analyzed through rasch analysis to determine whether the questionnaire can be used in clinical practice in this translated version. the following clinical parameters are evaluated: age, gender, preoperative and postoperative monocular distance uncorrected visual acuity (uva), distance best spectacle-corrected visual acuity (bscva) of the eye for cataract surgery, binocular distance uva and bscva, refraction, spherical equivalent (se), and intraocular pressure.

Eligibility criteria:
inclusion criteria: * patients with unilateral or bilateral senile cataract with stage 2 nuclear opalescence according to the lens opacities classification system iii (locs-3) grading scale, and no severe cognitive impairment during their preoperative examination. exclusion criteria: * patients with difficulty with the greek language or dementia, alzheimer's disease, severe stroke with mental disorder and conditions with the onset of mental retardation.

Keywords: cataract catquest validation questionnaire rasch analysis
restoration of arm function in people with high-level tetraplegia

Conditions: Incomplete Spinal Cord Injury

Summary: functional electrical stimulation (fes) has been used to activate paralysed muscles and restore movement after spinal cord injury and stroke. this technology involves the application of low-level electrical currents to the nerves and muscles to cause muscle contraction where the user's ability to achieve that through voluntary means has been lost. providing control of muscle contraction in a coordinated way can mean that users are able once again to produce functional movements in otherwise paralysed limbs. routine clinical use is limited to the prevention of drop foot in the lower limb following stroke and occasional therapeutic use in the hand and shoulder. systems providing functional reach and grasp, however, have not achieved clinical or commercial success. this project aims to develop methods for personalising assistive technology to restore arm function in people with high-level spinal cord injury. the investigators will use a combination of electrical stimulation to elicit forces in muscles no longer under voluntary control, and mobile arm supports to compensate for insufficient muscle force where necessary. the investigators will use computational models specific to an individual's functional limitations to produce patient-specific interventions. the project will be in three phases: building a model to predict the effects of electrical stimulation on a paralysed arm with arm support, development of methodologies using this model to optimise the arm support and stimulation system, and testing of stimulation controllers designed using this approach.


Eligibility criteria:
inclusion criteria: * patients with mid- to high-level spinal cord injury resulting in partial or full paralysis of the upper limb will be eligible for inclusion in the study. in addition, they must be: * able to give informed consent; * able to remain comfortably seated with provision of trunk stability; * medically stable and at least six weeks from injury; and * have sufficient passive range of motion without discomfort. exclusion criteria: * have orthopaedic implants across or between electrode sites; * have active cardiac implant; * have poor skin conditions, scar or carcinogenic tissue at site of stimulation; * have uncontrolled pain; * have uncontrolled epilepsy; * have skin reactions to electrodes; * have open wounds or injuries; and * are pregnant or planning for a pregnancy.
herbal teas on bone health in an osteopenic population

Conditions: Osteopenia

Summary: the project goal is to identify if herbal teas consumed three times per day over a period of three months can improve these markers of bone health as well as improve quality of life (qol) compared to women taking placebo by increasing osteoblast activity, decreasing osteoclast activity, increasing nocturnal melatonin levels and by decreasing c-reactive protein (crp) and cortisol levels. our central hypothesis is that these herbal teas will improve both objective and subjective measures of bone health in a population with osteopenia not taking this regimen by reducing osteoclast activity and increasing osteoblast activity and by reducing stress and anxiety.


Eligibility criteria:
inclusion criteria: * male or female with osteopenia (t-score between -1.0 and -2.5) * at least 18 years of age * must be willing to drink tea three times a day for 3 months * must also be willing to come to the study location on 4 occasions (baseline, end of month 1, end of month 2, and end of month 3), * must also be willing to come to the study location to provide urinary, salivary and fecal samples on 2 occasions (baseline and at the end of month 3), * must also be willing to come to the study location to have their blood pressure taken on 4 occasions (baseline, end of month 1, end of month 2, and end of month 3) * must be willing to come to the study location to complete questionnaires on 2 occasions (baseline and at the end of month 3) * must be willing to maintain daily diary for 4 months. exclusion criteria: * women or men with osteoporosis * women or men with osteopenia due to hyperparathyroidism, multiple myeloma, metastatic bone disease, chronic steroid use * women or men who are on any bone therapies (i.e. bisphosphonates, selective estrogen receptor modulators, hormone therapy, teriparatide, and denosumab) * women or men with chronic obstructive pulmonary disease (copd) * women or men who smoke
metronom continuous glucose monitoring system

Conditions: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabete Mellitus

Summary: the aim of the present study is to investigate the clinical performance of the metronom cgm system in patients with type 1 diabetes over a period of 14 days. in this study, the cgm sensor will be tested in an inpatient setting (meal/insulin test with frequent plasma glucose monitoring) at different days of wear-time. sensor data will be compared to gold standard reference (super gl2 analyser or ysi) and stability of sensor performance will be assessed over time. additionally, safety and tolerability of the sensor will be investigated by regular assessment of the insertion site.


Eligibility criteria:
inclusion criteria: * informed consent obtained after being advised of the nature of the study * male or female aged ≥18 years * type 1 diabetes for at least 6 months according to the who definition treated with multiple daily injections (mdi) or continuous subcutaneous insulin infusion (csii) for at least 3 months (for t1d only) * body mass index (bmi) \<35 kg/m² * flash or continuous glucose monitoring (fgm, cgm) user * willing and able to wear the metronom cgm system for the duration of the study and undergo all study procedures * hba1c ≤86 mmol/mol exclusion criteria: * any disease or condition which the investigator or treating physician feels would interfere with the trial or the safety of the subject * female of childbearing potential who is pregnant, breast-feeding or intend to become pregnant or is not using adequate contraceptive methods * any mental condition rendering the subject incapable of giving his consent * subject is using any medication that significantly impacts glucose metabolism (oral steroids) except if stable for at least the last three months and expected to remain stable for the study duration * has severe medical or psychological condition(s) or chronic conditions/infections that in the opinion of the investigator would compromise the subject's safety or successful participation in the study * subject is actively enrolled in another clinical trial * known adrenal gland problem, pancreatic tumour, or insulinoma * known bleeding disorder * known hypersensitivity to adhesive or skin lesions that hinder sensor insertion * inability of the subject to comply with all study procedures * inability of the subject to understand the subject information * subject donated blood in the last 3 months
effectiveness and safety of embosphere microspheres for embolization of the geniculate artery for the treatment of pain with known moderate to severe knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: the purpose of this research study is to evaluate the effectiveness and safety of a permanent embolic (embosphere microspheres) for embolization of the geniculate artery for the treatment of moderate to severe knee osteoarthritis.


Eligibility criteria:
inclusion criteria: * subject has signed informed consent * subject is age 40-80 * subject is able to have an mri * minimum of prior 12 weeks of failed response to conservative therapy for knee osteoarthritis, which may include one or more of: a) oral or topical nsaids, opioid medications, intra-articular injection of glucocorticoids or hyaluronic acid, physical therapy. * localized tenderness in anterior knee area * kellgren-lawrence grade 1, 2, or 3 as assessed by weight-bearing knee radiographs * synovitis present as assessed by worms * vas \>50 mm * womac score \>30 exclusion criteria: * rheumatoid arthritis * local infection of the target knee(s) * kellgren-lawrence grade \>3 * osteonecrosis evident by mri * prior knee arthroplasty * allergy to iodinated contrast agents that cannot be managed by prophylaxis * hypersensitivity to gelatin products * any known condition that limits catheter-based intervention or is a contraindication to embolization * active malignancy other than non-melanomatous skin cancer * subject is pregnant, breastfeeding, or pre-menopausal and intending to become pregnant * any other condition related to the subject's health and wellbeing deemed exclusionary in the opinion of the investigator
a study of the safety and effectiveness of infliximab (remicade) in patients with giant cell arteritis

Conditions: Giant Cell Arteritis

Summary: the purpose of this study is to evaluate the safety and efficacy (effectiveness) of infliximab (remicade) in patients with giant cell arteritis. infliximab (remicade) targets specific proteins in the body's immune system to help control the development of inflammation to help reduce painful disease.

the purpose of this study is to see if infliximab is safe and effective in treating gca. currently, the only treatment for gca is prednisone. gca is a long lasting inflammatory disease. the cause is unknown. it may affect all the arteries, but it focuses on the big vessels such as those around the heart, the vessels in the neck and head, and their major branches. it can lead to vision loss, blindness, stroke, stenosis (narrowing of blood vessels) and aneurysms (a weakening in the lining of the blood vessel wall, which may eventually lead to rupture of the blood vessel). the damage to the arteries is caused by an immune response. a naturally occurring substance in the immune system called "tumor necrosis factor alpha" (tnfa) plays a significant role in this immune response against the blood vessels. this response is thought to cause the long-lasting inflammation (irritation and swelling of the vessels). by blocking the effect of tnfa we think that we may reduce the signs and symptoms associated with gca. this trial will study patients who are stable on prednisone treatment by evaluating whether infliximab can control their symptoms as the dose of prednisone is reduced. patients will receive infusions of either 5mg/kg of infliximab or placebo at weeks 0, 2, 6, 14, 22, 30, 38, and 46. safety evaluations will be performed at specified intervals throughout the study and will consist of laboratory tests, vital signs (such as blood pressure), physical examinations and the occurrence and severity of adverse events as well as other study specific procedures. patients will receive receive infusions of either 5mg/kg infliximab or placebo infusions at weeks 0, 2, 6, 14, 22, 30, 38, and 46.

Eligibility criteria:
inclusion criteria: * patients who have a diagnosis of giant cell arteritis (gca) * patients who have a diagnosis of gca of = 4 weeks' duration * patients who are receiving = 40 mg/day of prednisone/prednisolone exclusion criteria: * patients must not have a prior diagnosis of gca \> 4 weeks * patients must not have failed to respond to glucocorticosteroid therapy within 5 days of initiation of therapy.

Keywords: giant cell arteritis infliximab
effect of a synbiotic on symptoms of patients with stc

Conditions: Slow Transit Constipation

Summary: to evaluate the efficacy of synbiotic (bificopec) containing enterococci, bifidobacteria, lactobacilli triple viable bacteria and pectin in patients with slow transit constipation.

chronic constipation has become a common, often chronic, functional gastrointestinal disease which influences the quality of life all over the world. a total of 100 patients diagnosed as slow transit constipation (stc) using rome iii criteria were randomized to receive either synbiotic or placebo twice daily for 12 weeks. the primary efficacy endpoint was the clinical remission and improvement rate at week 4 and 12. stool frequency and consistency, colonic transit time (ctt), evacuation and abdominal symptoms, patient assessment of constipation symptoms (pac-sym scores), gastrointestinal quality-of-life index (giqli), satisfaction scores and adverse events were also monitored.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years; 2. bmi: 18.5-25kg/m2; 3. chronic constipation was diagnosed according to romeⅲ criteria; 4. colonic transit time (ctt) \>48 hours; 5. mild-to-moderate constipation with wexner constipation scale between 16 and 25. exclusion criteria: 1. megacolon, intestinal obstruction, inflammatory bowel disease, and cancer; 2. secondary constipation (i.e. drugs, endocrine disorders, neurological disorders, metabolic disorders, psychological disorders or abdominal surgery); 3. severe anterior rectocele or full thickness rectorectal intussusception according to defecography; 4. pregnant or lactating women; 5. infection with enteric pathogen; 6. usage of antibiotics or proton pump inhibitors (ppis); 7. hepatic, renal, cardiovascular, respiratory or psychiatric disease; 8. other diseases or factors evaluated by the investigator which could influence intestinal transit or intestinal microbiota.

Keywords: synbiotic soluble dietary fiber slow transit constipation microbiota